Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1795 | Thyroid cancer | ICEECE2012

Ret somatic mutations are not an early event in the tumoral transformation of sporadic medullary thyroid cancer

Romei C. , Cosci B. , Ugolini C. , Bottici V. , Molinaro E. , Agate L. , Tacito A. , Basolo F. , Miccoli P. , Pinchera A. , Elisei R.

The reported prevalence of RET somatic mutations in sporadic MTC is about 40–50% and the most frequent somatic mutation is Met918Thr in exon 16. MTC harboring a somatic RET mutation have been demonstrated to have a more advanced stage at diagnosis and a worse outcome. Although RET mutations are believed to be driving events in the MTC tumorigenesis only the finding of somatic mutations in microMTC can confirm this hypothesis.Aim of the present work ...

ea0029p1758 | Thyroid cancer | ICEECE2012

BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated thyroid cancer patients: a 5 year follow up study

Viola D , Torregrossa L , Giannini R , Ugolini C , Biagini A , Romei C , Molinaro E , Agate L , Basolo F , Pinchera A , Vitti P , Elisei R

BRAFV600E mutation is the most frequent genetic alteration (29–83%) of papillary thyroid carcinoma (PTC). Many authors have demonstrated that the presence of the mutation is associated with a more advanced tumor stage at diagnosis and a worse outcome but anyone assessed if BRAFV600E mutation could be useful prognostic marker in low risk PTC patients (T1-T2N0M0, 7th TNM classification).Aim of this study was to evaluate if the presence of BRAFV600E mu...